Activity of Cefotaxime and Amikacin against 14,272 Gram-Negative Bacteria from Clinical Samples in the Period 1980 to 1985 Diego DámasoM. P. Sánchez-MorenoR. M. Daza Section 1: The Current Situation on Bacterial Resistance to Third Generation Cephalosporins 27 October 2012 Pages: 1 - 5
Effect of a Single Dose of Cefotaxime or Ceftriaxone on Human Faecal Flora M. Michéa-HamzehpourR. AuckenihalerJ.-C. Pechère Section 1: The Current Situation on Bacterial Resistance to Third Generation Cephalosporins 27 October 2012 Pages: 6 - 11
Evaluation of the in Vitro Susceptibility of Gram-Negative Bacilli to Cefotaxime, over a Period of 3 Years Jorge MurilloManuel GuzmánClara Ocero Section 1: The Current Situation on Bacterial Resistance to Third Generation Cephalosporins 27 October 2012 Pages: 12 - 13
In Vitro Activity of Cefotaxime against Clinically Significant Pathogens Satoshi NakashioMasao Nakamura Section 1: The Current Situation on Bacterial Resistance to Third Generation Cephalosporins 27 October 2012 Pages: 14 - 21
Emergence of Resistance during β-Lactam Therapy of Gram-Negative Infections Jean-Claude Pechère Section 1: The Current Situation on Bacterial Resistance to Third Generation Cephalosporins 27 October 2012 Pages: 22 - 28
Cefotaxime Combined with Selective Decontamination in Long Term Intensive Care Unit Patients H. K. F. van SaeneC. P. StoutenbeekD. F. Zandstra Section 1: The Current Situation on Bacterial Resistance to Third Generation Cephalosporins 27 October 2012 Pages: 29 - 34
Evaluation of Bactericidal Activity of Cefotaxime and Other β-Lactams by a Novel Method Giuseppe SattaGiuseppe CornagliaRaffaello Pompei Section 1: The Current Situation on Bacterial Resistance to Third Generation Cephalosporins 27 October 2012 Pages: 35 - 40
A Regional Survey of the Resistance to β-Lactam Antibiotics in Clinical Isolates of (Facultative) Aerobic Micro-organisms E. E. StobberinghJ. M. H. PhilipsC. P. A. van Boven Section 1: The Current Situation on Bacterial Resistance to Third Generation Cephalosporins 27 October 2012 Pages: 41 - 44
The Synergistic Effect of Cefotaxime and Desacetylcefotaxime against Clinical Isolates of Anaerobic Bacteria H. R. DevlinL. Boskovski Section 2: Desacetylcefotaxime and Cefotaxime: Implications of a Bactericidal Metabolite 27 October 2012 Pages: 45 - 50
Pharmacokinetics of Cefotaxime and Desacetylcefotaxime in Elderly Patients E. LudwigÉ. SzékelyH. Graber Section 2: Desacetylcefotaxime and Cefotaxime: Implications of a Bactericidal Metabolite 27 October 2012 Pages: 51 - 56
In Vitro Activity of Desacetylcefotaxime and the Interaction with its Parent Compound, Cefotaxime Kohtaro OizumiI. HayashiK. Konno Section 2: Desacetylcefotaxime and Cefotaxime: Implications of a Bactericidal Metabolites 27 October 2012 Pages: 57 - 61
Comparison of in Vitro Activity of Cefotaxime and Desacetylcefotaxime Alone and in Combination against 320 Gram-Negative Clinical Isolates G. PiédrolaI. GalanM. C. Maroto Section 2: Desacetylcefotaxime and Cefotaxime: Implications of a Bactericidal Metabolites 27 October 2012 Pages: 62 - 64
Serum and Renal Tissue Concentrations of Cefotaxime in Urinary Tract Obstruction in Rabbits Kiichiro TagoNoboru YabusakiAkira Ueno Section 2: Desacetylcefotaxime and Cefotaxime: Implications of a Bactericidal Metabolites 27 October 2012 Pages: 65 - 71
Serum and Tissue Concentrations of Cefoxitin and Cefotaxime in Women Undergoing Hysterectomy R. L. WhiteCharles H. NightingaleW. H. Tripp Section 2: Desacetylcefotaxime and Cefotaxime: Implications of a Bactericidal Metabolites 27 October 2012 Pages: 72 - 77
Pharmacokinetics of Cefotaxime and Desacetylcefotaxime in Renal Failure Patients Undergoing Continuous Arteriovenous Haemofiltration H. HasegawaK. TakahashiA. Horiuchi Short Communication 27 October 2012 Pages: 78 - 81
Comparative Study of the Pharmacokinetics of Various β-Lactams after Intravenous and Intraperitoneal Administration in Patients Undergoing Continuous Ambulatory PeritoneaL Dialysis Akio ImadaNobuo ItagakiAtsushi Horiuchi Short Communication 27 October 2012 Pages: 82 - 87
Study on Transfer of Cefotaxime into Bone Tissue Tomosaburo MakiyamaTomiaki Asai Short Communication 27 October 2012 Pages: 88 - 92
Pharmacokinetics of Cefotaxime in Elderly Patients Hiroshi SugiharaKimihiro YoneyamaToru Shimizu Short Communication 27 October 2012 Pages: 93 - 96
Prophylaxis of Infection by Selective Decontamination in Mechanically Ventilated Patients S. J. A. AerdtsR. van DalenE. J. Vollaard Short Communication 27 October 2012 Pages: 97 - 99
Preventative Antibiotics for Penetrating Abdominal Trauma — Single Agent or Combination Therapy? Brack A. BivinsLarry CrotsH. Mathilda Horst Section 3: Newer Experiences with Cefotaxime in Prophylaxis 27 October 2012 Pages: 100 - 105
Cefotaxime plus Metronidazole Appears More Effective than Piperacillin in the Prevention of Postappendicectomy Wound Sepsis J. B. BourkeT. W. BalfourL. MacShane Section 3: Newer Experiences with Cefotaxime in Prophylaxis 27 October 2012 Pages: 106 - 110
Cefotaxime in the Prophylaxis of Otorhinolaryngological Cancer Surgery P. GehannoN. Moisythe multieentre study group Short Communication 27 October 2012 Pages: 111 - 115
Cefotaxime Single-Dose Surgical Prophylaxis in a Prepaid Group Practice Ronald N. JonesJerry M. SlepackWilliam V. Wojeski Section 3: Newer Experiences with Cefotaxime in Prophylaxis 27 October 2012 Pages: 116 - 123
Cefotaxime and Flucloxacillin as Antibiotic Prophylaxis in Cardiac Transplantation A. KhaghaniM. MartinM. H. Yacoub Short Communication 27 October 2012 Pages: 124 - 126
Cefotaxime Lavage in Children Undergoing Appendicectomy T. A. McAllisterA. H. B. FyfeP. A. M. Raine Section 3: Newer Experiences with Cefotaxime in Prophylaxis 27 October 2012 Pages: 127 - 132
Comparison of the Antimicrobial Prophylactic Efficacy of Cefotaxime and Cephazolin in Obstetric and Gynaecological Surgery Piero PeritiT. Mazzeithe Italian Gynecologic Study Group for Antimicrobial Prophylaxis Section 3: Newer Experiences with Cefotaxime in Prophylaxis 27 October 2012 Pages: 133 - 138
Three Approaches to Prophylactic Antibiotics in Elective Gastrointestinal Tract Surgery C. A. V. PerrottO. B. W. GreeffS. Scott Short Communication 27 October 2012 Pages: 139 - 140
Antibiotic Prophylaxis in Aortic and Peripheral Arterial Surgery in the Presence of Infected Extremity Lesions J. V. RobbsE. ReddyR. Ray Section 3: Newer Experiences with Cefotaxime in Prophylaxis 27 October 2012 Pages: 141 - 150
Prophylactic Use of Cefotaxime in Biliary Surgery Comparison of Single-Dose versus Multiple-Dose Schedule Renato CastoldiG. FerrariV. DiCarlo Short Communication 27 October 2012 Pages: 151 - 153
Antibiotic Prophylaxis for Surgery after Vesico-Ureteral Reflux in Children Lionel Couprisa multicentre randomised study group Short Communication 27 October 2012 Pages: 154 - 157
Prophylactic Use of Cefotaxime in Biliary Surgery L. Guyotthe multicentre study group Short Communication 27 October 2012 Pages: 158 - 160
Prophylaxis in Elective Colorectal Surgery Francisco Hernàndez GómezA. Segura VivesM. Galera Rodriguez Short Communication 27 October 2012 Pages: 161 - 162
Impact of Cefotaxime and Ceftriaxone on the Bowel and Vaginal Flora after Single-Dose Prophylaxis in Vaginal Hysterectomy H. H. BräutigamH. KnotheR. Rangoonwala Section 4: Further Clinical Experiences and Studies of Tolerability with Cefotaxime 27 October 2012 Pages: 163 - 168
A Randomised Prospective Comparison of Cefotaxime versus Netilmicin/Penicillin for Treatment of Suspected Neonatal Sepsis M. A. HallD. A. DuckerD. S. Cole Section 4: Further Clinical Experiences and Studies of Tolerability with Cefotaxime 27 October 2012 Pages: 169 - 177
Studies of Enzymuria and β2-Microglobulinuria in Patients Receiving Prophylactic Cefotaxime in Obstetric and Gynaecological Surgery Mutsuo IshikawaKohki YamashitaTetsuya Shimizu Section 4: Further Clinical Experiences and Studies of Tolerability with Cefotaxime 27 October 2012 Pages: 178 - 180
Influence of Cefotaxime on Renal Function during the Treatment of Infections F. IwabuchiA. ShimadaM. Hatano Section 4: Further Clinical Experiences and Studies of Tolerability with Cefotaxime 27 October 2012 Pages: 181 - 184
Cefotaxime Treatment of Gram-Negative Enteric Meningitis in Infants and Children Richard F. Jacobs Section 4: Further Clinical Experiences and Studies of Tolerability with Cefotaxime 27 October 2012 Pages: 185 - 189
Clinical Experience with Cefotaxime in Internal Medicine between 1981 and 1984 Pramod M. ShahM. WieselW. Stille Short Communication 27 October 2012 Pages: 190 - 194
Efficacy of a Combination of Cefotaxime, Tobramycin and Vancomycin as Antibiotic Therapy for Neutropenia F. BrunetJ. J. LanoreJ. F. Monsallier Short Communication 27 October 2012 Pages: 195 - 195
Effects of Cefotaxime on Blood Coagulation in Patients with Renal Insufficiency Yoshikazu FujitaSeiji InoueTakeo Goto Short Communication 27 October 2012 Pages: 196 - 198
Cefotaxime versus Chloramphenicol for Ampicillin-Resistant Haemophilus influenzae Meningitis Jean-Rock LapointeLuc Chicoine Short Communication 27 October 2012 Pages: 199 - 202
Cefotaxime in the Treatment of Severe Bacterial Pneumonia in Paediatric Patients Franca RusconiL. RancilioA. Villa Short Communication 27 October 2012 Pages: 203 - 204
Effects of Antibiotics on Platelet Aggregation Keisuke SunakawaHironobu AkitaYasuo Ichihashi Short Communication 27 October 2012 Pages: 205 - 207
Computer Modelling Antibiotic Therapy Costs Herbert E. Gladen Section 5: Considerations on Dosing and Cost Effectiveness 27 October 2012 Pages: 208 - 213
The Value of Twice-Daily Cefotaxime in Lower Respiratory Tract Infections J. KosmidisA. TsougranisT. Diamantis Short Communication 27 October 2012 Pages: 214 - 215
Optimal Duration of Cefotaxime Prophylaxis in Abdominal and Vaginal Hysterectomy P. J. McDonaldR. SandersO. Petrucco Short Communication 27 October 2012 Pages: 216 - 220
Cefotaxime Optimal Dosage in Adult Patients Alain SimonCatherine Aumont d’AubracClaude Carbon Section 5: Considerations on Dosing and Cost Effectiveness 27 October 2012 Pages: 221 - 230
Comparison of Two versus Three Daily Infusions of Cefotaxime plus Amikacin in Granulocytopenic Children Jean-Pierre VannierM. Gardembas-PainP. Tron Short Communication 27 October 2012 Pages: 231 - 231
